Dr. James Hayman came to the Department of Radiation Oncology following his Residency in 1996. He is a Professor and the Director of the Clinical Division and a 2014 ASTRO Fellow and 2018 ASCO Fellow. Dr. Hayman's clinical research interests include the management of lung, esophageal, breast, skin, ocular and central nervous system malignancies. He is active in health services research, serves as a Co-Director of the Michigan Radiation Oncology Quality Consortium (MROQC), and is a national leader of quality improvement efforts in Radiation Oncology.
Areas of Interest
Health service research
- Quality of care
- Lung cancer
- Esophageal cancer
- Breast cancer
- Skin cancer
- Ocular malignancies
- Central nervous system malignancies
Honors & Awards
- 2018 Fellow, American Society for Clinical Oncology (FASCO)
- 2014 Fellow, American Society for Therapeutic Radiation Oncology (FASTRO)
- MD, University of Chicago Pritzker School of Medicine, 1991
- MBA, University of Chicago Graduate School of Business, 1991
- Radiation Oncology Residency, Joint Center for Radiation Therapy at Harvard Medical School 1996
- Board certifications: Radiation Oncology, Hospice & Palliative Medicine
- (PI:Pierce), 2/1/11 – 12/31/22, Michigan Blue Cross Blue Shield: The Michigan Radiation Oncology Quality Consortium, Role: Co-Director.
Published Articles or Reviews
Selected from 159 publications
- Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M. NCCN guidelines insights: Small cell lung cancer, version 2.2018. J Natl Compr Canc Netw. 16(10):1171-1182, 2018. PM30323087.
- Jagsi R, Griffith KA, Moran JM, Ficaro E, Marsh R, Dess RT, Chung E, Liss AL, Hayman JA, Mayo CS, Flaherty K, Corbett J, Pierce L. A randomized comparison of radiation therapy techniques in the management of node-positive breast cancer: Primary outcomes analysis. Int J Radiat Oncol Biol Phys. 101(5):1149-1158, 2018. PM30012527.
- Matuszak MM, Paximadis P, Yudelev M, Grubb M, Wilson ML, Fraser C, Dalmia P, Alkhatib A, Sieffert DE, Haywood JR, Tatro D, Parker J, Ettaher O, Grills I, Kestin L, Walker EM, Friedle C, Kim H, Radawski JD, Boike T, Moran JM, Pierce LJ, Hayman JA: Managing motion in conventionally fractionated lung cancer radiation therapy: Collaborative quality improvement from a statewide consortium of academic and community practices. Pract Radiat Oncol. 8(4):e208-e211, 2018. PM29452864.
- Spratt DE, Mancini BR, Hayman JA, Boike T, Pierce LJ, Moran JM, Dominello MM, Fireman M, Griffith K, Jolly S; Michigan Radiation Oncology Quality Consortium. Contemporary statewide practice pattern assessment of the palliative treatment of bone metastasis. Int J Radiat Oncol Biol Phys. 101(2):462-467, 2018. PM29726364.
- Lee JS, Durham AB, Bichakjian CK, Harms PW, Hayman JA, McLean SA, Harms KL, Burns WR. Completion lymph node dissection or radiation therapy for sentinel node metastasis in Merkel cell carcinoma. Ann Surg Oncol. 26(2):386-394, 2019. PM30556118
- Jagsi R, Griffith KA, Vicini F, Boike T, Burmeister J, Dominello MM, Grills I, Hayman JA, Moran JM, Paximadis P, Radawski JD, Walker EM, Pierce LJ, Michigan Radiation Oncology Quality Consortium: Toward Improving Patients' Experiences of Acute Toxicity from Breast Radiotherapy: Insights from the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort. J Clin Oncol 38(34): 4019-4029, 2020. PM32986529.